Active Pass Pharmaceuticals Elects New Chairman of the Board and Adds Industry Veteran as a Director.Business Editors & Health/Medical Writers BIOWIRE2K VANCOUVER, British Columbia--(BW HealthWire)--April 22, 2002 Active Pass Pharmaceuticals announced today that Ken Galbraith has been elected chairman of the board of directors, and that Dr. Jeffrey McKelvy has been elected as a director. Galbraith replaces Dr. William Hunter, who is stepping down from the board of directors. "We look forward to working closely with Mr. Galbraith as Active Pass fortifies its position as the industry leader in ABC ABC in full American Broadcasting Co. Major U.S. television network. It began when the expanding national radio network NBC split into the separate Red and Blue networks in 1928. transporter drug discovery. We are also pleased to add Dr. McKelvy's breadth of experience to our Board," said Dr. Peter Reiner, president and chief executive officer of Active Pass. "We are also especially grateful to Dr. Hunter for the time and effort he has put into stewardship of our board over the past two years." Galbraith was previously executive vice president and chief financial officer of QLT Inc. where he raised more than $500 million in equity capital and negotiated strategic alliances with large healthcare companies including Novartis AG, Baxter Healthcare Corp., American Home Products Corporation and the Beaufour Ipsen Group. Prior to joining QLT, Galbraith was a chartered accountant with Thorne Riddell, Chartered Accountants, a predecessor to KPMG KPMG Klynveld Peat Marwick Goerdeler (accounting firm) KPMG Kaiser Permanente Medical Group KPMG Keiner Prüft Mehr Genau (German) KPMG Kommen Prüfen Meckern Gehen LLP. Galbraith is currently president of Gigha Consulting, a technology consulting and investment management company, and is also director of Angiotech Pharmaceuticals, Kinetek Pharmaceuticals, Micrologix Biotech and Stressgen Biotechnologies. He is a former founding director and chairman of the B.C. Biotechnology Alliance and is currently chair of the Canadian Bacterial Diseases Network. Galbraith received his B. Com. (honours) in 1985 from the University of British Columbia Locations Vancouver The Vancouver campus is located at Point Grey, a twenty-minute drive from downtown Vancouver. It is near several beaches and has views of the North Shore mountains. The 7. and is a Chartered Accountant. McKelvy is currently president and CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. of Avera Pharmaceuticals, a specialty pharmaceutical company based in San Diego. Previous to that, McKelvy was vice president of Merck Research Laboratories and Site Head for San Diego. He assumed that position following Merck's 1999 acquisition of SIBIA Neurosciences where he held the position of executive vice president, chief scientific officer and director. McKelvy was the founding CEO of Trophix Pharmaceuticals until its acquisition by Allelix Pharmaceuticals, and held management positions at both Abbott Laboratories and CIBA CIBA Canadian Intercollegiate Baseball Association CIBA Chemical Industry in Basle CIBA Cayman Islands Bankers Association CIBA Californian Indian Basketweavers Association . Prior to joining the pharmaceutical industry in 1987, McKelvy was professor of Neurobiology Neurobiology Study of the development and function of the nervous system, with emphasis on how nerve cells generate and control behavior. The major goal of neurobiology is to explain at the molecular level how nerve cells differentiate and develop their , Molecular Biology, and Psychiatry at SUNY SUNY - State University of New York Stony Brook. McKelvy received his Ph.D in Biochemistry from Johns Hopkins University Johns Hopkins University, mainly at Baltimore, Md. Johns Hopkins in 1867 had a group of his associates incorporated as the trustees of a university and a hospital, endowing each with $3.5 million. Daniel C. . Active Pass Pharmaceuticals is a private biotechnology company involved in the discovery and early clinical development of drugs that target a family of proteins known as ABC transporters. Found in cells throughout the body, these molecular pumps are associated with chronic diseases with large potential markets, including age-related macular degeneration Age-related macular degeneration (ARMD) Degeneration of the macula (the central part of the retina where the rods and cones are most dense) that leads to loss of central vision in people over 60. , Alzheimer's disease, lipid disorders, and diabetes. Active Pass, which is headquartered in Vancouver B.C., has adopted a proprietary chemogenomic strategy in which arrays of human ABC transporters are tested against carefully selected chemical libraries in order to simultaneously identify compounds with potency, selectivity and bioavailability. |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion